(Q43048287)

12 November 2017

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial (English)

1 reference

12 November 2017

1 reference

14

1 reference

12 November 2017

Alessandra Mangia

1

1 reference

12 November 2017

Nicola Minerva

2

1 reference

12 November 2017

Donato Bacca

3

1 reference

12 November 2017

Raffaele Cozzolongo

4

1 reference

12 November 2017

Giovanni L Ricci

5

1 reference

12 November 2017

Vito Carretta

6

1 reference

12 November 2017

Francesco Vinelli

7

1 reference

12 November 2017

Gaetano Scotto

8

1 reference

12 November 2017

Giuseppe Montalto

9

1 reference

12 November 2017

Mario Romano

10

1 reference

12 November 2017

Giuseppe Cristofaro

11

1 reference

12 November 2017

Leonardo Mottola

12

1 reference

12 November 2017

Fulvio Spirito

13

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

12 November 2017

1 reference

12 November 2017

47

1 reference

12 November 2017

43-50

1 reference

12 November 2017

1

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

7 January 2021

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

7 January 2021

Short-term treatment duration for HCV-2 and HCV-3 infected patients

1 reference

7 January 2021

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

7 January 2021

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

7 January 2021

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

1 reference

7 January 2021

Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.

1 reference

7 January 2021

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

1 reference

7 January 2021

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

7 January 2021

External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis

1 reference

7 January 2021

Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

7 January 2021

Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.22061

1 reference

release_3fkxsvjnpza3pbatdgetjggwrq

12 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3fkxsvjnpza3pbatdgetjggwrq

24 November 2022

mapped directly with Wikidata item

1 reference